Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as Tigason.

CAS：54350-48-0
中文别名：替维甲;阿维A酯;全反式-9-(4-甲氧基-2,3,6-三甲基苯基)-3,7-二甲基-2,4,6,8-壬四烯酸乙酯;
英文别名：Etretinato;ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate;Etretinato [INN-Spanish];Ro 10-9359;Etretinatum [INN-Latin];ethyl (all-E)-9-(4-methyoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate;Retinoid;Etretinatum;ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate;Tegison;9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-oic acid ethyl ester;Ethyl etrinoate;
分子式：C23H30O3
分子量：354.483
精确质量：354.219
Psa：35.53
Logp：5.6455

UNII：65M2UDR9AG

外观与性状：结晶固体
密度：1.006g/cm3
沸点：506.4ºC at 760 mmHg
熔点：104-105ºC
闪点：219.4ºC
折射率：1.544
储存条件：Amber Vial, -20ºC Freezer